Another thing to remember is that cardiocel is steadily becoming the main source of revenue for Admedus. In the HY ending Dec 2014 cardiocel only accounted for 21% of AHZ revenue. By HY ending Dec 2015 that had grown to 35% (ie. $2.3 million out of $6.5 million).
Soon cardiocel will produce more than 50% of AHZ revenue. So future cardiocel growth will have a more direct impact on quarterly revenue than we've seen in the past.
Another thing to remember is that cardiocel is steadily becoming...
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.00 |
Change
0.035(0.19%) |
Mkt cap ! $346.0M | |||
| Open | High | Low | Value | Volume |
| $18.00 | $18.00 | $17.65 | $75.19K | 4.184K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 414 | $17.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.10 | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |